SRR26320067
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.460
- MYOGENESIS+0.420
- WNT_BETA_CATENIN_SIGNALING+0.380
- TGF_BETA_SIGNALING+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- HEDGEHOG_SIGNALING+0.310
- HEME_METABOLISM+0.210
- APICAL_JUNCTION+0.200
- COAGULATION+0.160
- HYPOXIA+0.150
Top 10 suppressed
- E2F_TARGETS-0.630
- MYC_TARGETS_V2-0.600
- G2M_CHECKPOINT-0.570
- MYC_TARGETS_V1-0.480
- MTORC1_SIGNALING-0.460
- ALLOGRAFT_REJECTION-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.430
- INTERFERON_GAMMA_RESPONSE-0.380
- INTERFERON_ALPHA_RESPONSE-0.360
- DNA_REPAIR-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296806 | — | — | 0.905 |
| 2 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.901 |
| 3 | SRR1313111 | — | A | 0.883 |
| 4 | SRR8613705 | — | A | 0.882 |
| 5 | TCGA-BH-A0EA-01A-11R-A115-07 | — | A | 0.871 |
| 6 | TCGA-A7-A5ZX-01A-12R-A29R-07 | — | A | 0.868 |
| 7 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.865 |
| 8 | 87fad31a-da7d-4904-93bd-29a7290a316b | — | — | 0.864 |
| 9 | SRR8943020 | — | — | 0.858 |
| 10 | SRR10900010 | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| MYOGENESIS | 0.420 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.010 | Idelalisib | — uncovered |